NASDAQ: MLYS Mineralys Therapeutics, Inc. 10-Q

Mineralys submits NDA for lorundrostat, receives Dec 2026 PDUFA date; removes tariff risks

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MLYS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.